OPINION
ResMed Inc. (RMD) $22.17
The RMD story has been well documented over recent weeks as the combination of Ozempic and a disappointing result has seen the stock plunge ~30%. The uncertainty that the weight loss drug (actually for diabetes) has created is weighing heavily on potentially impacted stocks, with the true impact likely to take years to unfold Read moreResMed Inc (RMD) $23.76
ResMed (RMD) is enduring a tough quarter having already fallen -27.6%, making it the 8th worst-performing stock in the ASX200. The issue has been two-fold: a disappointing result in August and fears that weight loss drugs such as Ozempic will become prevalent, reducing the demand for RMD’s sleep apnea products. Read moreResMed Inc (RMD) $25.53
RMD has been rerated on the downside following a disappointing earnings report with weaker margins the catalyst for the selling as the stock was priced for expansion! However while the result wasn’t good the selling gathered momentum as investors’ focused on weight loss “miracle drugs” reducing the demand for RMD’s sleep disorder products – the negative sentiment feels entrenched and our concern is it may take months to dissipate. Read moreResMed Inc. (RMD) $26.08
RMD has been walloped over -25% from its August high following its disappointing earnings result, 4Q revenue was a touch below consensus but the market was caught off guard by weaker margins when expectations were for expansion. Read moreResMed Inc (RMD) $26.91
RMD dropped another -5.2% yesterday on follow through selling from this month’s disappointing result but its been a weak market this week, RMD has traded ex-dividend and the stock is only down -2% for the week so far i.e. not too bad in our opinion, although another tough session played out overnight in the US. Read moreFlagship Growth Portfolio – Amendments
We are making multiple changes to the Flagship Growth Portfolio. Read more
